Drug Access Listing

Tablet, PO

• 60mg 

• 240mg 

60mg: 02478374 

240mg: 02540185 

Criteria for initial 12-month coverage: For the treatment of non-metastatic castration-resistant prostate cancer patients (nmCRPC) who meet all the following criteria: 

• used in combination with androgen deprivation therapy (ADT); and  

• have no detectable distant metastases by either CT, MRI or technetium-99m bone scan; and 

• are at high risk* of developing metastases; and 

• have no risk factors for seizures; and - have a good Eastern Cooperative Oncology Group status (ECOG) performance status (0 or 1).  

* high risk is defined as a prostate-specific antigen doubling time of <= 10 months during continuous ADT.  

Criteria for renewal every 12 months: There is no objective evidence of radiographic disease progression or unacceptable toxicity. 

NIHB Drug Benefit List 

Janssen (Janssen BioAdvance Patient Assistance Program):  

https://www.bioadvancemember.ca/s/reimbursement-support?language=en_US

Tablet, PO

• 60mg 

• 240mg 

60mg: 02478374 

240mg: 02540185 

Criteria for initial 12-month coverage: For the treatment of metastatic castration-sensitive prostate cancer patients (mCSPC) who meet all the following criteria: 

• used in combination with androgen deprivation therapy (ADT); and 

• patient is castration sensitive (i.e., no prior ADT or within six months of beginning ADT); and 

• have a good ECOG performance status (0 or 1). 

Criteria for renewal every 12 months: There is no objective evidence of radiographic disease progression or unacceptable toxicity.

NIHB Drug Benefit List 

Janssen (Janssen BioAdvance Patient Assistance Program):  

https://www.bioadvancemember.ca/s/reimbursement-support?language=en_US

60 mg / Syr Injection 

02545411 

Pending 

Haven: 

Drug Access Canada - Haven by Sentrex 

Inj. Sol.  
120 mg /1.7mL 

02545764 

Pending  

Haven: 

Drug Access Canada - Haven by Sentrex 

7.5mg-30mg mg / Syr Injection 

3.75mg = 00884502,

7.5mg = 00836273,

11.25mg = 02239834,

22.5mg = 02230248,

30mg = 02239833 

Public benefit 

Haven: 

Drug Access Canada - Haven by Sentrex 

100 mg tab | 150 mg tab

100mg: 02475200 | 150mg: 02475219

Funded as per NIHB criteria: 

• Criteria for initial 12-month coverage: 

• For the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC); and  

• Olaparib is used as monotherapy; and 

• Patient has good performance status; and 

• Patient has progressed following prior treatment with a new hormonal agent/androgen-receptor-axis-targeted therapy (ARAT); and 

• Patient has deleterious or suspected deleterious mutations (germline or somatic) in the homologous recombination repair (HRR) genes BRCA or ATM. 

NIHB Drug Benefit List 

AstraZeneca Patient Support Program: Access Here

AstraZeneca Patient Assistance Program: Access Here

120mg tablet 

02542137  

Pending (Positive CDA decision: relugolix | CDA-AMC)  

Copay cards available from manufacturer